Most recent changes to the CPT® Category I New and Revised Vaccine Codes Long Descriptor document

- Updated long code descriptor with correct description and removed the resequenced (#) and new (●) symbols for code 90739
- Removed hyphen (-) from “subunit” in code 90750
- Removal of the FDA approval pending symbol (~) from code 90750 following the October 20, 2017 notification that this product has been granted FDA approval status
- Updated the FDA approval date from October 20, 2018 to October 20, 2017 for code 90750
- Removal of the FDA approval pending symbol (~) from code 90739 following the November 9, 2017 notification that this product has been granted FDA approval status
- Updated the FDA approval date from November 9, 2018 to November 9, 2017 for code 90739

The following Vaccine codes were accepted at the May 2016 CPT Editorial Panel meeting for the 2018 CPT production cycle. These codes are effective on January 1, 2017 following the six month implementation period which begins July 1, 2016.

<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Released to AMA website</th>
<th>Effective</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>●90682</td>
<td>Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use</td>
<td>July 1, 2016</td>
<td>January 1, 2017</td>
<td>CPT® 2018</td>
</tr>
<tr>
<td>#●90750</td>
<td>Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use</td>
<td>July 1, 2016</td>
<td>January 1, 2017</td>
<td>CPT® 2018</td>
</tr>
</tbody>
</table>

The following Vaccine codes were accepted or revised at the September/October 2016 CPT Editorial Panel meeting for the 2018 CPT production cycle. These codes are effective on July 1, 2017 following the six month implementation period which begins January 1, 2017.

<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Released to AMA website</th>
<th>Effective</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>#■90587</td>
<td>Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use</td>
<td>January 1, 2017</td>
<td>July 1, 2017</td>
<td>CPT® 2018</td>
</tr>
<tr>
<td>#▲90620</td>
<td>Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use</td>
<td>January 1, 2017</td>
<td>July 1, 2017</td>
<td>CPT® 2018</td>
</tr>
</tbody>
</table>
CPT® Category I New and Revised Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Released to AMA website</th>
<th>Effective</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>#▲90621</td>
<td>Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use</td>
<td>January 1, 2017</td>
<td>July 1, 2017</td>
<td>CPT® 2018</td>
</tr>
<tr>
<td>▲90651</td>
<td>Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use</td>
<td>January 1, 2017</td>
<td>July 1, 2017</td>
<td>CPT® 2018</td>
</tr>
</tbody>
</table>

The following Vaccine code was accepted at the June 2017 CPT Editorial Panel meeting for the 2018 CPT production cycle. This code is effective on January 1, 2018 following the six month implementation period which begins July 1, 2017.

<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Released to AMA website</th>
<th>Effective</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>#●90756</td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use</td>
<td>July 1, 2017</td>
<td>January 1, 2018</td>
<td>CPT® 2018</td>
</tr>
</tbody>
</table>

FDA Approval Notifications

These revisions follow notification that this product had been granted FDA approval status on the date indicated. Code 90750 was originally published in CPT 2018.

<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Released to AMA website</th>
<th>FDA Approval</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>#●90750</td>
<td>Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use</td>
<td>November 6, 2017</td>
<td>October 20, 2017</td>
<td>CPT® 2019</td>
</tr>
</tbody>
</table>

These revisions follow notification that this product had been granted FDA approval status on the date indicated. Code 90739 was originally published in CPT 2013.

<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Released to AMA website</th>
<th>FDA Approval</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>90739</td>
<td>Hepatitis B vaccine (HepB), adult dosage, 2 dose schedule, for intramuscular use</td>
<td>November 20, 2017</td>
<td>November 9, 2017</td>
<td>CPT® 2019</td>
</tr>
</tbody>
</table>